Coagulopathy is a major extrapulmonary risk factor for mortality in hospitalized patients with COVID-19 with type 2 diabetes
Introduction To investigate the risk factors for the death in patients with COVID-19 with type 2 diabetes mellitus (T2DM).Research design and methods We retrospectively enrolled inpatients with COVID-19 from Wuhan Jinyintan Hospital (Wuhan, China) between December 25, 2019, and March 3, 2020. The epidemiological and clinical data were compared between non-T2DM and T2DM or between survivors and non-survivors. Univariable and multivariable Cox regression analyses were used to explore the effect of T2DM and complications on in-hospital death.Results A total of 1105 inpatients with COVID-19, 967 subjects with without T2DM (n=522 male, 54.0%) and 138 subjects with pre-existing T2DM (n=82 male, 59.4%) were included for baseline characteristics analyses. The complications were also markedly increased in patients with pre-existing T2DM, including acute respiratory distress syndrome (ARDS) (48.6% vs 32.3%, p<0.001), acute cardiac injury (ACI) (36.2% vs 16.7%, p<0.001), acute kidney injury (AKI) (24.8% vs 9.5%, p<0.001), coagulopathy (24.8% vs 11.1%, p<0.001), and hypoproteinemia (21.2% vs 9.4%, p<0.001). The in-hospital mortality was significantly higher in patients with pre-existing T2DM compared with those without T2DM (35.3% vs 17.4%, p<0.001). Moreover, in hospitalized patients with COVID-19 with T2DM, ARDS and coagulopathy were the main causes of mortality, with an HR of 7.96 (95% CI 2.25 to 28.24, p=0.001) for ARDS and an HR of 2.37 (95% CI 1.08 to 5.21, p=0.032) for coagulopathy. This was different from inpatients with COVID-19 without T2DM, in whom ARDS and cardiac injury were the main causes of mortality, with an HR of 12.18 (95% CI 5.74 to 25.89, p<0.001) for ARDS and an HR of 4.42 (95% CI 2.73 to 7.15, p<0.001) for cardiac injury.Conclusions Coagulopathy was a major extrapulmonary risk factor for death in inpatients with COVID-19 with T2DM rather than ACI and AKI, which were well associated with mortality in inpatients with COVID-19 without T2DM..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
---|---|
Enthalten in: |
BMJ Open Diabetes Research & Care - 8(2020), 2 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ying Chen [VerfasserIn] |
---|
Links: |
doi.org [kostenfrei] |
---|
Themen: |
---|
doi: |
10.1136/bmjdrc-2020-001851 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
DOAJ062448048 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ062448048 | ||
003 | DE-627 | ||
005 | 20230309021210.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230228s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1136/bmjdrc-2020-001851 |2 doi | |
035 | |a (DE-627)DOAJ062448048 | ||
035 | |a (DE-599)DOAJ136f7b7ae7414456be921d904153e2b7 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RC648-665 | |
100 | 0 | |a Ying Chen |e verfasserin |4 aut | |
245 | 1 | 0 | |a Coagulopathy is a major extrapulmonary risk factor for mortality in hospitalized patients with COVID-19 with type 2 diabetes |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Introduction To investigate the risk factors for the death in patients with COVID-19 with type 2 diabetes mellitus (T2DM).Research design and methods We retrospectively enrolled inpatients with COVID-19 from Wuhan Jinyintan Hospital (Wuhan, China) between December 25, 2019, and March 3, 2020. The epidemiological and clinical data were compared between non-T2DM and T2DM or between survivors and non-survivors. Univariable and multivariable Cox regression analyses were used to explore the effect of T2DM and complications on in-hospital death.Results A total of 1105 inpatients with COVID-19, 967 subjects with without T2DM (n=522 male, 54.0%) and 138 subjects with pre-existing T2DM (n=82 male, 59.4%) were included for baseline characteristics analyses. The complications were also markedly increased in patients with pre-existing T2DM, including acute respiratory distress syndrome (ARDS) (48.6% vs 32.3%, p<0.001), acute cardiac injury (ACI) (36.2% vs 16.7%, p<0.001), acute kidney injury (AKI) (24.8% vs 9.5%, p<0.001), coagulopathy (24.8% vs 11.1%, p<0.001), and hypoproteinemia (21.2% vs 9.4%, p<0.001). The in-hospital mortality was significantly higher in patients with pre-existing T2DM compared with those without T2DM (35.3% vs 17.4%, p<0.001). Moreover, in hospitalized patients with COVID-19 with T2DM, ARDS and coagulopathy were the main causes of mortality, with an HR of 7.96 (95% CI 2.25 to 28.24, p=0.001) for ARDS and an HR of 2.37 (95% CI 1.08 to 5.21, p=0.032) for coagulopathy. This was different from inpatients with COVID-19 without T2DM, in whom ARDS and cardiac injury were the main causes of mortality, with an HR of 12.18 (95% CI 5.74 to 25.89, p<0.001) for ARDS and an HR of 4.42 (95% CI 2.73 to 7.15, p<0.001) for cardiac injury.Conclusions Coagulopathy was a major extrapulmonary risk factor for death in inpatients with COVID-19 with T2DM rather than ACI and AKI, which were well associated with mortality in inpatients with COVID-19 without T2DM. | ||
653 | 0 | |a Diseases of the endocrine glands. Clinical endocrinology | |
700 | 0 | |a Jie Xu |e verfasserin |4 aut | |
700 | 0 | |a Xiaoyan Chen |e verfasserin |4 aut | |
700 | 0 | |a Chaomin Wu |e verfasserin |4 aut | |
700 | 0 | |a Ming Wei |e verfasserin |4 aut | |
700 | 0 | |a Yen-cheng Chao |e verfasserin |4 aut | |
700 | 0 | |a Juan Song |e verfasserin |4 aut | |
700 | 0 | |a Dongni Hou |e verfasserin |4 aut | |
700 | 0 | |a Yuye Zhang |e verfasserin |4 aut | |
700 | 0 | |a Chunling Du |e verfasserin |4 aut | |
700 | 0 | |a Xiaoying Li |e verfasserin |4 aut | |
700 | 0 | |a Yuanlin Song |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t BMJ Open Diabetes Research & Care |d BMJ Publishing Group, 2016 |g 8(2020), 2 |w (DE-627)DOAJ000046922 |x 20524897 |7 nnns |
773 | 1 | 8 | |g volume:8 |g year:2020 |g number:2 |
856 | 4 | 0 | |u https://doi.org/10.1136/bmjdrc-2020-001851 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/136f7b7ae7414456be921d904153e2b7 |z kostenfrei |
856 | 4 | 0 | |u https://drc.bmj.com/content/8/2/e001851.full |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2052-4897 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_DOAJ | ||
951 | |a AR | ||
952 | |d 8 |j 2020 |e 2 |